CD36 and metabolic dysfunction-associated steatotic liver disease: Given the fact that CD36 increases HBV replication to a certain level, we speculate that for those HBV infected patients with a higher expression level of CD36, such as NAFLD and MS, proper control of CD36 or metabolism treatment may serve as an adjunctive therapeutic means which may have an additive effect to the conventional anti-viral drugs such as interferon and reverse-transcriptase inhibitors.